Successful Desensitization With ELX/TEZ/IVA


KOCACIK UYGUN D. F., Kaya M. A., Bankoglu B., BAŞARAN A. E., BİNGÖL A.

Journal of Pediatric Pharmacology and Therapeutics, cilt.29, sa.5, ss.539-543, 2024 (Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 29 Sayı: 5
  • Basım Tarihi: 2024
  • Doi Numarası: 10.5863/1551-6776-29.5.539
  • Dergi Adı: Journal of Pediatric Pharmacology and Therapeutics
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.539-543
  • Anahtar Kelimeler: CFTR modulator, cystic fibrosis, desensitization, ELX/TEZ/IVA, Trikafta
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was given US Food and Drug Administration approval based on its therapeutic benefits to treat patients with cystic fibrosis (CF) who had at least 1 allele of the CF transmembrane conductance regulator (CFTR) with phenylalanine deleted at position 508 (F508del). The increase in genotyping studies has increased the frequency of use of CFTR modulators; however, severe allergic reactions to CFTR modulators have also been described. It is critical to avoid the offending medication and select alternative treatments while dealing with drug allergies. Drug desensitization may be taken into consideration in situations where there is no other option. This article describes home desensitization treatment for a patient with CF who developed a maculopapular rash following CFTR modulator medication. There are currently no alternative drugs for CFTR modulators, which are crucial for patients with CF, and limited experience is available with allergic reactions to these drugs. It is important to establish desensitization protocols in order to control drug reactions to CFTR modulators, which are vital for individuals with CF.